Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study

Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study

Abstract Background Upadacitinib (UPA) is a selective JAK inhibitor recently approved for the treatment of psoriatic arthritis (PsA). In this post-approval study, we aimed to evaluate the effectiveness and safety of UPA over 24 weeks and identify clinical predictors of response, in a multicentric co...

Full description

Bibliographic Details
Main Authors: Michele Maria Luchetti Gentiloni, Valentino Paci, Antonio Carletto, Alen Zabotti, Roberta Ramonda, Maria Sole Chimenti, Lorenzo Dagna, Nicoletta Luciano, Anna Piccinelli, Ivan Giovannini, Giovanni Striani, Nicola Boffini, Gilda Sandri, Niccolò Possemato, Ilenia Pantano, Devis Benfaremo, Carlo Salvarani, Francesco Ciccia, Carlo Selmi, Gianluca Moroncini
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Arthritis Research & Therapy
Subjects:
Psoriatic arthritis
Upadacitinib
Clinical efficacy
Real life
Psoriasis
Peripheral arthritis
Online Access:https://doi.org/10.1186/s13075-023-03182-9

Internet

https://doi.org/10.1186/s13075-023-03182-9

Similar Items